Otsuka Holdings defies pharmaceutical conventions. Founded in 1921 in Tokushima, Japan, it operates with equal seriousness across pharmaceuticals and nutraceuticals , producing both one of the best-selling psychiatric drugs in history and one of Asia’s most recognized sports drinks. In FY2024, the company posted record revenue of ¥2,329.9 billion ($28.0 billion), operating across 120 countries with 35,338 employees.
Pharmaceutical companies generally do one thing. They discover molecules, shepherd them through clinical trials, manufacture them at scale, and sell them to doctors and hospitals. Otsuka does that. It also makes Pocari Sweat.
That juxtaposition is not a corporate accident. Otsuka Holdings describes itself as a “total healthcare” company, and the phrase is not marketing language , it is a structural description. The company operates two distinct verticals with separate management, separate R&D pipelines, and separate distribution networks. The pharmaceutical business develops novel treatments for central nervous system disorders, nephrology, and oncology. The nutraceutical business produces functional beverages, nutritional supplements, and consumer health products. The two sides share a parent company, a founding family, and little else.
This structure has its origins in the company’s 1921 founding in Tokushima Prefecture on the island of Shikoku. Busaburo Otsuka started a chemical manufacturing business. Over the following decades, the family expanded into intravenous solutions, then pharmaceuticals, then consumer nutrition. The diversification was not a strategy imported from a consulting deck. It was the organic accumulation of a century of family-led commercial instincts. By the time Otsuka Holdings went public on the Tokyo Stock Exchange in 2010, the conglomerate encompassed entities that ranged from psychiatric drug development to sports drink bottling.
The molecule that defined Otsuka’s pharmaceutical ambitions was aripiprazole, marketed as Abilify. Developed in-house and launched in partnership with Bristol-Myers Squibb in 2002, Abilify introduced a new mechanism of action in psychiatry: partial dopamine agonism. Previous antipsychotics either blocked dopamine receptors entirely (first-generation drugs with severe side effects) or blocked them selectively (second-generation atypicals with metabolic risks). Aripiprazole took a third path, modulating dopamine activity rather than simply suppressing it.
The market response was extraordinary. Abilify became one of the best-selling pharmaceutical products in history, reaching peak annual sales of approximately $7.5 billion before its US patent expired in 2015. At one point, it was the top-selling drug in the United States by revenue. For a company headquartered in Tokushima , not Tokyo, not New York, not Basel , this was an improbable outcome. Otsuka had built a global psychiatric franchise from a provincial Japanese city.
The loss of Abilify exclusivity forced a reckoning. Otsuka had invested the Abilify years in developing a successor: brexpiprazole, marketed as Rexulti. Like aripiprazole, brexpiprazole is a partial dopamine agonist, but with a modified receptor-binding profile designed to reduce the akathisia (restlessness) that some patients experienced with Abilify. Rexulti launched in 2015, the same year Abilify went generic. The timing was not coincidental. Otsuka had spent over a decade preparing for the patent cliff, and Rexulti was the bridge.
Otsuka’s pharmaceutical portfolio extends well beyond psychiatry. Jynarque (tolvaptan) treats autosomal dominant polycystic kidney disease (ADPKD), a genetic condition that affects roughly 12.5 million people worldwide. Tolvaptan was originally developed as a vasopressin receptor antagonist for hyponatremia , a condition of dangerously low blood sodium. But Otsuka’s researchers discovered that blocking vasopressin receptors in the kidney also slowed cyst growth in ADPKD. The repurposing of tolvaptan from a cardiology drug to a nephrology drug is one of the more consequential examples of indication expansion in recent pharmaceutical history.
On the nutraceutical side, Pocari Sweat occupies a position in Asian consumer culture that has no direct Western equivalent. Launched in 1980, the isotonic beverage was designed to mimic the electrolyte composition of human body fluid. It became ubiquitous across Japan, Southeast Asia, and the Middle East , not through aggressive marketing but through steady distribution expansion over four decades. Oronamin C, a carbonated vitamin drink launched in 1965, holds a similar cultural position in Japan. These are not sideline businesses. Otsuka’s nutraceutical division generates billions in annual revenue and operates its own manufacturing and R&D infrastructure.
The duality of the business creates an unusual financial profile. When pharmaceutical revenues dip , as they did after the Abilify patent cliff , the nutraceutical and consumer products divisions provide stability. When consumer spending softens, the pharmaceutical pipeline carries the weight. Between FY2023 and FY2024, total revenue surged from $15.2 billion to $28.0 billion, driven by the pharmaceutical division’s growth and favourable currency effects. It was the kind of revenue jump that would look suspicious in a single-product company. In a conglomerate with Otsuka’s breadth, it reflected the convergence of multiple growth drivers arriving simultaneously.
Sources: Otsuka Holdings Co., Ltd. Annual Reports and Integrated Reports. Tokyo Stock Exchange (TSE: 4578). OPPI member directory.